Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DTIL Stock Forecast 2026-2027
$7.69
Current Price
$193.03M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DTIL Price Targets
+680.2%
To High Target of $60.00
+218.6%
To Median Target of $24.50
+147.1%
To Low Target of $19.00
DTIL Price Momentum
+5.6%
1 Week Change
+16.3%
1 Month Change
+49.9%
1 Year Change
+84.9%
Year-to-Date Change
-12.8%
From 52W High of $8.82
+117.8%
From 52W Low of $3.53
📊 TOP ANALYST CALLS
Did DTIL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Precision BioSciences is one of their latest high-conviction picks.
Latest DTIL Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, DTIL has a bullish consensus with a median price target of $24.50 (ranging from $19.00 to $60.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $7.69, the median forecast implies a 218.6% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 680.2% upside. Conversely, the most conservative target is provided by Debjit Chattopadhyay at Guggenheim, suggesting a 147.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DTIL Analyst Ratings
4
Buy
0
Hold
0
Sell
DTIL Price Target Range
Low
$19.00
Average
$24.50
High
$60.00
Current: $7.69
Latest DTIL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DTIL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 17, 2026 | Jones Trading | Catherine Novack | Buy | Assumes | $30.00 |
| May 21, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Mar 28, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Mar 19, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Feb 19, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Jan 10, 2025 | BMO Capital | Kostas Biliouris | Outperform | Upgrade | $34.00 |
| Aug 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| May 30, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| May 16, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Apr 30, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Initiates | $19.00 |
| Apr 17, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Mar 28, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $60.00 |
| Feb 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $3.00 |
| Sep 19, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $3.00 |
| Aug 17, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $3.00 |
| Aug 7, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $N/A |
| Jul 28, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jul 28, 2023 | BTIG | Thomas Shrader | Buy | Maintains | $2.00 |
| Jun 1, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $17.00 |
Precision BioSciences Inc (DTIL) Competitors
The following stocks are similar to Precision BioSciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DTIL
Precision BioSciences
mkt cap
187.85M
Precision BioSciences Inc (DTIL) Financial Data
Precision BioSciences Inc has a market capitalization of $193.03M with a P/E ratio of 4.4x. The company generates $34.26M in trailing twelve-month revenue with a -133.4% profit margin.
Revenue growth is +5,261.1% quarter-over-quarter, while maintaining an operating margin of +36.6% and return on equity of -62.7%.
Valuation Metrics
Market Cap
$193.03M
Enterprise Value
$97.44M
P/E Ratio
4.4x
PEG Ratio
-2.3x
Price/Sales
5.6x
Growth & Margins
Revenue Growth (YoY)
+5,261.1%
Gross Margin
N/A
Operating Margin
+36.6%
Net Margin
-133.4%
EPS Growth
+5,261.1%
Financial Health
Cash/Price Ratio
+60.8%
Current Ratio
13.3x
Debt/Equity
31.2x
ROE
-62.7%
ROA
-22.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Precision BioSciences Inc (DTIL) Business Model
About Precision BioSciences Inc
What They Do
Develops gene editing therapies for diseases.
Business Model
The company uses its proprietary ARCUS genome editing platform to create in vivo gene editing therapies targeting genetic and infectious diseases. It generates revenue through licensing agreements with partners, while also pursuing its own clinical programs aimed at treating conditions like chronic hepatitis B and Duchenne muscular dystrophy.
Additional Information
Founded in 2006 and based in Durham, North Carolina, Precision BioSciences aims to address high unmet medical needs with innovative gene editing solutions. Its key programs focus on precise DNA modifications, and it maintains a portfolio that includes partnerships for additional therapeutic applications.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
68
CEO
Mr. Michael Amoroso
Country
United States
IPO Year
2015
Website
precisionbiosciences.comPrecision BioSciences Inc (DTIL) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates
Nuvation Bio (NUVB) delivered earnings and revenue surprises of -91.30% and +0.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 04, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
3 days ago
Quick Summary
Precision BioSciences (Nasdaq: DTIL) reported Q1 2026 financial results, advancing its PBGENE-HBV program into new cohorts as part of its gene editing therapies for unmet medical needs.
Why It Matters
Precision BioSciences' progress in gene editing and advancing clinical programs signals potential breakthroughs in high unmet need diseases, impacting future revenue and investment opportunities.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Precision BioSciences (DTIL) reported a quarterly loss of $0.34 per share, worse than the expected loss of $0.27, and an improvement from a loss of $2.21 per share a year prior.
Why It Matters
Precision BioSciences reported a larger quarterly loss than expected, indicating potential operational challenges. The significant year-over-year improvement in losses may reflect progress but raises concerns about future profitability.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) will release its Q1 2026 financial results and business update on May 5, 2026. The company focuses on in vivo gene editing therapies.
Why It Matters
Precision BioSciences’ upcoming financial results and business update could signal shifts in its growth trajectory, impacting stock performance and investor sentiment in the gene editing sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Precision BioSciences has activated its first clinical trial site for PBGENE-DMD, a gene editing therapy for Duchenne muscular dystrophy, and patient enrollment has begun for the Phase 1 trial.
Why It Matters
The activation of the first clinical trial site for PBGENE-DMD signals progress in Precision BioSciences' gene editing pipeline, potentially boosting investor confidence and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Precision BioSciences announced that preclinical data from its PBGENE-DMD program will be presented at the ASGCT 2026 Annual Meeting in Boston, scheduled for May 11-15, 2026.
Why It Matters
Acceptance of preclinical data for oral presentation highlights Precision BioSciences' progress in gene editing. Positive outcomes could enhance investor confidence and drive stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
14 days ago
Quick Summary
Precision BioSciences granted 7,094 RSUs to a new employee on April 20, 2026, under its 2021 Employment Inducement Plan, as approved by its Compensation Committee.
Why It Matters
The grant of restricted stock units (RSUs) signals confidence in attracting talent, which can drive innovation and growth in Precision BioSciences' gene editing efforts, potentially impacting stock value.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About DTIL Stock
What is Precision BioSciences Inc's (DTIL) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Precision BioSciences Inc (DTIL) has a median price target of $24.50. The highest price target is $60.00 and the lowest is $19.00.
Is DTIL stock a good investment in 2026?
According to current analyst ratings, DTIL has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DTIL stock?
Wall Street analysts predict DTIL stock could reach $24.50 in the next 12 months. This represents a 218.6% increase from the current price of $7.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Precision BioSciences Inc's business model?
The company uses its proprietary ARCUS genome editing platform to create in vivo gene editing therapies targeting genetic and infectious diseases. It generates revenue through licensing agreements with partners, while also pursuing its own clinical programs aimed at treating conditions like chronic hepatitis B and Duchenne muscular dystrophy.
What is the highest forecasted price for DTIL Precision BioSciences Inc?
The highest price target for DTIL is $60.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 680.2% increase from the current price of $7.69.
What is the lowest forecasted price for DTIL Precision BioSciences Inc?
The lowest price target for DTIL is $19.00 from Debjit Chattopadhyay at Guggenheim, which represents a 147.1% increase from the current price of $7.69.
What is the overall DTIL consensus from analysts for Precision BioSciences Inc?
The overall analyst consensus for DTIL is bullish. Out of 8 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $24.50.
How accurate are DTIL stock price projections?
Stock price projections, including those for Precision BioSciences Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 2:36 AM UTC